248 related articles for article (PubMed ID: 17148582)
1. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.
Scheinberg P; Fischer SH; Li L; Nunez O; Wu CO; Sloand EM; Cohen JI; Young NS; John Barrett A
Blood; 2007 Apr; 109(8):3219-24. PubMed ID: 17148582
[TBL] [Abstract][Full Text] [Related]
2. Reactivation and dynamics of cytomegalovirus and Epstein-Barr virus after rabbit antithymocyte globulin and cyclosporine for aplastic anemia.
Park SS; Cho SY; Han E; Min GJ; Park S; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Cho SG; Lee JW
Eur J Haematol; 2019 Oct; 103(4):433-441. PubMed ID: 31381187
[TBL] [Abstract][Full Text] [Related]
3. Valganciclovir suppressed Epstein Barr virus reactivation during immunosuppression with alemtuzumab.
Gill H; Hwang YY; Chan TS; Pang AW; Leung AY; Tse E; Kwong YL
J Clin Virol; 2014 Apr; 59(4):255-8. PubMed ID: 24507802
[TBL] [Abstract][Full Text] [Related]
4. High incidence of cytomegalovirus, human herpesvirus-6, and Epstein-Barr virus reactivation in patients receiving cytotoxic chemotherapy for adult T cell leukemia.
Ogata M; Satou T; Kawano R; Yoshikawa T; Ikewaki J; Kohno K; Ando T; Miyazaki Y; Ohtsuka E; Saburi Y; Kikuchi H; Saikawa T; Kadota J
J Med Virol; 2011 Apr; 83(4):702-9. PubMed ID: 21328386
[TBL] [Abstract][Full Text] [Related]
5. Regular virologic surveillance showed very frequent cytomegalovirus reactivation in patients treated with alemtuzumab.
Cheung WW; Tse E; Leung AY; Yuen KY; Kwong YL
Am J Hematol; 2007 Feb; 82(2):108-11. PubMed ID: 17013817
[TBL] [Abstract][Full Text] [Related]
6. Co-Reactivation of Cytomegalovirus and Epstein-Barr Virus Was Associated With Poor Prognosis After Allogeneic Stem Cell Transplantation.
Zhou JR; Shi DY; Wei R; Wang Y; Yan CH; Zhang XH; Xu LP; Liu KY; Huang XJ; Sun YQ
Front Immunol; 2020; 11():620891. PubMed ID: 33664733
[TBL] [Abstract][Full Text] [Related]
7. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
8. [Epstein Barr viral load monitoring in mononuclear lymphocytes and serum of renal transplant recipients using a quantitative PCR protocol].
Merlino C; Giacchino F; Bergallo M; Bonello F; Bollero C; Segoloni GP; Cavallo R
G Ital Nefrol; 2003; 20(2):170-5. PubMed ID: 12746803
[TBL] [Abstract][Full Text] [Related]
9. Activity of alemtuzumab monotherapy in treatment-naive, relapsed, and refractory severe acquired aplastic anemia.
Scheinberg P; Nunez O; Weinstein B; Scheinberg P; Wu CO; Young NS
Blood; 2012 Jan; 119(2):345-54. PubMed ID: 22067384
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia.
Calistri E; Tiribelli M; Battista M; Michelutti A; Corbellino M; Viale P; Fanin R; Damiani D
Am J Hematol; 2006 May; 81(5):355-7. PubMed ID: 16628717
[TBL] [Abstract][Full Text] [Related]
11. Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.
Park SH; Choi SM; Lee DG; Choi JH; Yoo JH; Kim SH; Kim HJ; Cho SG; Eom KS; Lee JW; Min WS; Shin WS; Kim CC
Transpl Infect Dis; 2009 Oct; 11(5):413-23. PubMed ID: 19708893
[TBL] [Abstract][Full Text] [Related]
12. Graft-versus-host disease following marrow transplantation for aplastic anemia: different impact of two GVHD prevention strategies.
Siegal D; Xu W; Sutherland R; Kamel-Reid S; Kuruvilla J; Lipton JH; Minden M; Messner H; Gupta V
Bone Marrow Transplant; 2008 Jul; 42(1):51-6. PubMed ID: 18372907
[TBL] [Abstract][Full Text] [Related]
13. Incidence and dynamics of Epstein-Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation.
Carpenter B; Haque T; Dimopoulou M; Atkinson C; Roughton M; Grace S; Denovan S; Fielding A; Kottaridis PD; Griffiths P; Mackinnon S; Emery V; Chakraverty R
Transplantation; 2010 Sep; 90(5):564-70. PubMed ID: 20555307
[TBL] [Abstract][Full Text] [Related]
14. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
15. No indication of increased infection rates using low-dose alemtuzumab instead of anti-thymocyte globulin as graft-versus-host disease prophylaxis before allogeneic stem cell transplantation.
Neumann T; Schneidewind L; Thiele T; Pink D; Schulze M; Schmidt C; Krüger W
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29178248
[TBL] [Abstract][Full Text] [Related]
16. Differential Reactivation of Cytomegalovirus and Epstein-Barr Virus in Patients with B Cell Lymphoma.
Hatayama Y; Watanabe K; Ichikawa H; Kawamura K; Fukuda T; Motokura T
Viral Immunol; 2023 Oct; 36(8):520-525. PubMed ID: 37440168
[TBL] [Abstract][Full Text] [Related]
17. An Epstein-Barr virus-associated leukemic lymphoma in a patient treated with rabbit antithymocyte globulin and cyclosporine for hepatitis-associated aplastic anemia.
Ohata K; Iwaki N; Kotani T; Kondo Y; Yamazaki H; Nakao S
Acta Haematol; 2012; 127(2):96-9. PubMed ID: 22178718
[TBL] [Abstract][Full Text] [Related]
18. Cytomegalovirus DNAemia and disease: incidence, natural history and management in settings other than allogeneic stem cell transplantation.
Ng AP; Worth L; Chen L; Seymour JF; Prince HM; Slavin M; Thursky K
Haematologica; 2005 Dec; 90(12):1672-9. PubMed ID: 16330442
[TBL] [Abstract][Full Text] [Related]
19. Limited predictive value of real-time quantitative PCR cytomegalovirus monitoring in the blood. Fatal CMV pneumonia in an autologous stem cell transplant recipient previously treated with alemtuzumab.
Halaburda K; Nasiłowska-Adamska B; Grabarczyk P; Szczepiński A; Szpila T; Warzocha K; Mariańska B
Ann Transplant; 2007; 12(2):37-40. PubMed ID: 18173065
[TBL] [Abstract][Full Text] [Related]
20. Case report: persistent cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation using in vivo alemtuzumab: emergence of resistant CMV due to mutations in the UL97 and UL54 genes.
Oshima K; Kanda Y; Kako S; Asano-Mori Y; Watanabe T; Motokura T; Chiba S; Shiraki K; Kurokawa M
J Med Virol; 2008 Oct; 80(10):1769-75. PubMed ID: 18712833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
